Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Tumors don't just lose the Y chromosome — they chip away at it strategically. A new study reveals that cancer cells selectively delete gene-rich regions of the Y chromosome to drive tumor growth, disrupt immune responses, and reshape stress and growth pathways. The findings could open the door to targeted therapies for male cancer patients.
A new study published in Communications Biology is rewriting what we thought we knew about Y chromosome loss in cancer. Rather than an all-or-nothing disappearing act, researchers found that cancer cells selectively chip away at specific, gene-rich regions of the Y chromosome — and those deletions have far-reaching consequences for how tumors grow and evade the immune system.
Led by Dr. Dan Theodorescu of the University of Arizona Cancer Center, the team analyzed genome sequencing data from 160 male cancer cell lines and developed a novel scoring tool — the Y EroSion Score (YES) — to map Y chromosome loss as a continuous spectrum rather than a binary event. They identified 24 protein-coding genes recurrently lost in cancer, with no equivalent deletions found in healthy men from the 1000 Genomes Project, confirming these are acquired changes, not inherited ones.
Why it matters: Y chromosome loss has already been linked to higher cancer mortality in men. This study provides a detailed map of which regions are lost and why — laying the groundwork for targeted therapies and potentially using Y chromosome erosion as an early cancer warning signal.
